financetom
Business
financetom
/
Business
/
FrontView REIT Says IPO Underwriters Exercised Option to Buy Additional Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FrontView REIT Says IPO Underwriters Exercised Option to Buy Additional Shares
Oct 23, 2024 1:23 AM

04:02 AM EDT, 10/23/2024 (MT Newswires) -- FrontView REIT ( FVR ) said Tuesday that the underwriters of its initial public offering have exercised their option to buy an additional of about 1.1 million common shares at the IPO price of $19 per share, less underwriting discounts and commissions.

The option closing is expected to settle Wednesday. The company said it sold a total of about 14.3 million common shares in the offering for gross proceeds of about $271.5 million, after giving effect to the option closing.

The company's common stock started trading on the New York Stock Exchange on Oct. 2, under the ticker symbol, "FVR."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Archer Aviation raises $300 million in BlackRock-backed funding
Archer Aviation raises $300 million in BlackRock-backed funding
Feb 11, 2025
Feb 11 (Reuters) - Air-taxi maker Archer Aviation ( ACHR ) said on Tuesday it has raised $300 million in a funding round that consisted of institutional investors including accounts managed by BlackRock ( BLK ). Archer expects the capital raise to help it accelerate the development of its hybrid aircraft platform and further reinforce its balance sheet. We are...
Travere Therapeutics Completes US FDA Meeting Ahead of Potential Kidney Disease Drug Submission
Travere Therapeutics Completes US FDA Meeting Ahead of Potential Kidney Disease Drug Submission
Feb 11, 2025
08:28 AM EST, 02/11/2025 (MT Newswires) -- Travere Therapeutics ( TVTX ) said Tuesday that it has completed a meeting with the US Food and Drug Administration and plans to submit a supplemental New Drug Application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder. The application is based on the drug's mid-stage...
DuPont Q4 Earnings: 7% Sales Growth, Higher Margins, Electronics Boom And More
DuPont Q4 Earnings: 7% Sales Growth, Higher Margins, Electronics Boom And More
Feb 11, 2025
DuPont De Nemours, Inc ( DD ). shares are trading higher after the company's fourth-quarter results exceeded street estimates. The company reported sales growth of 7% year over year to $3.092 billion, beating the consensus of $3.068 billion. Organic sales increased +7% YoY, with an 8% increase in volume offset by a 1% decrease in price. Organic sales by region...
GlobalFoundries forecasts weak Q1 amid tariff concerns and smartphone sector struggles
GlobalFoundries forecasts weak Q1 amid tariff concerns and smartphone sector struggles
Feb 11, 2025
Feb 11 (Reuters) - GlobalFoundries ( GFS ) on Tuesday forecast first-quarter revenue and profit below Wall Street estimates as the contract chipmaker braces for the potential impact of President Donald Trump's tariffs on automaker clients and a challenging smartphone market in 2025. Shares of the Malta, New York State-based company were down 5.1% before the bell. GlobalFoundries ( GFS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved